Table of Contents

company-logo

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.

Valerio Therapeutics Dividend Announcement

• Valerio Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Valerio Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Valerio Therapeutics Dividend History

Valerio Therapeutics Dividend Yield

Valerio Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Valerio Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Valerio Therapeutics Financial Ratios

P/E ratio-0.59
PEG ratio-0.01
P/B ratio2.89
ROE-208.83%
Payout ratio0.00%
Current ratio0.90
Quick ratio0.90
Cash Ratio0.41

Valerio Therapeutics Dividend FAQ

Does Valerio Therapeutics stock pay dividends?
Valerio Therapeutics does not currently pay dividends to its shareholders.
Has Valerio Therapeutics ever paid a dividend?
No, Valerio Therapeutics has no a history of paying dividends to its shareholders. Valerio Therapeutics is not known for its dividend payments.
Why doesn't Valerio Therapeutics pay dividends?
There are several potential reasons why Valerio Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Valerio Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Valerio Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Valerio Therapeutics a dividend aristocrat?
Valerio Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Valerio Therapeutics a dividend king?
Valerio Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Valerio Therapeutics a dividend stock?
No, Valerio Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Valerio Therapeutics stocks?
To buy Valerio Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Valerio Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.